Shield Therapeutics has completed a fundraising
Shield Therapeutics plc has raised funds to bolster the expansion of ACCRUFeR®, the sole FDA-approved therapy for iron deficiency and to drive the business. Additionally, it positions the company for further investments.
Shield Therapeutics is a patient-focused, commercial-stage pharmaceutical company on a mission to improve the lives of people suffering from iron deficiency, enabling them to enjoy the things that make a difference in their everyday lives. Its lead medicine ACCRUFeR® (ferric maltol), is a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anemia.
Oaklins Cavendish, based in the UK, assisted Shield Therapeutics in securing its funding package.
![](/api/deal-hero-image/109370/deal-hero-image.jpg)
![](/api/deal-party-images/109370/deal-parties.png)
Sprechen Sie mit dem Deal-Team
Geoff Nash
Oaklins Cavendish
Relevante Transaktionen
Winking Studios Limited completes a secondary fundraising of US$20 million
Winking Studios has successfully raised US$20 million to fund its business strategy and future plans, such as strategic acquisitions, alliances and joint ventures as well as secondary or dual listings, to grow the group’s market share and broaden its customer base globally.
Weitere InformationenFRP Advisory Group plc has finalized a successful secondary placing
FRP Advisory Group plc has completed a fundraising. The book was oversubscribed and approximately £20.4 million (US$33 million) of shares were sold by certain directors and partners of FRP to new and existing institutional investors at 128 pence per ordinary share.
Weitere InformationenLeika Medical Equipments Ltd. has been acquired by Angus Capital
The shareholders of Leika Medical Equipments Ltd. have sold the company to Angus Capital.
Weitere Informationen